Future Directions in Therapies for Acute Respiratory Distress Syndrome

Jonathan E Millar; Kiran Reddy; Lieuwe D J Bos

doi:10.1016/j.ccm.2024.08.014

Future Directions in Therapies for Acute Respiratory Distress Syndrome

Clin Chest Med. 2024 Dec;45(4):943-951. doi: 10.1016/j.ccm.2024.08.014. Epub 2024 Sep 20.

Authors

Jonathan E Millar¹, Kiran Reddy², Lieuwe D J Bos³

Affiliations

¹ Baillie-Gifford Pandemic Science Hub, Centre for Inflammation Research, Institute for Repair and Regeneration, University of Edinburgh, The Roslin Institute, Easter Bush Campus, Midlothian, Edinburgh EH25 9RG, UK; Department of Critical Care, Queen Elizabeth University Hospital, Glasgow, UK.
² Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, University Road, Belfast BT7 1NN, UK.
³ Intensive Care Department, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam 1105 AZ, the Netherlands. Electronic address: [email protected].

PMID: 39443010
DOI: 10.1016/j.ccm.2024.08.014

Abstract

Acute respiratory distress syndrome (ARDS) is caused by a complex interplay among hyperinflammation, endothelial dysfunction, and alveolar epithelial injury. Targeted treatments toward the underlying pathways have been unsuccessful in unselected patient populations. The first reliable biological subphenotypes reflective of these biological disease states have been identified in the past decade. Subphenotype targeted intervention studies are needed to advance the pharmacologic treatment of ARDS.

Keywords: ARDS; Inflammation; Phenotype; Treatment.

Publication types

Review

MeSH terms

Humans
Respiratory Distress Syndrome* / physiopathology
Respiratory Distress Syndrome* / therapy